PMID- 16767432
OWN - NLM
STAT- MEDLINE
DCOM- 20070213
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 56
IP  - 2
DP  - 2007 Feb
TI  - Induction of an effective anti-tumor immune response and tumor regression by 
      combined administration of IL-18 and Apoptin.
PG  - 181-92
AB  - Immunization strategies using plasmid DNA can potentially improve humoral and 
      cellular immune responses that protect against cancer and infectious diseases. 
      The chicken anemia virus-derived Apoptin protein exhibits remarkable specificity 
      in its ability to induce apoptosis in tumor cells, but not in normal diploid 
      cells. Interleukin-18 (IL-18) is a Th1-type cytokine that has demonstrated 
      potential as a biological adjuvant in murine tumor models. In this study, we 
      analyzed the anti-tumor potential and mechanism of action of simultaneous Apoptin 
      and IL-18 gene transfer in C57BL/6 mice bearing Lewis lung carcinoma (LLC). Here 
      we report that the growth of established tumors in mice immunized with pAPOPTIN 
      in conjunction with pIL-18 was significantly inhibited compared with the growth 
      of tumors in mice immunized with the empty vector (EV) or pAPOPTIN alone. 
      Furthermore, the immunization of mice with pAPOPTIN in conjunction with pIL-18 
      elicited strong natural killer activity and LLC tumor-specific cytotoxic T 
      lymphocyte (CTL) responses in vitro. In addition, T cells from lymph nodes of 
      mice vaccinated with pIL-18 or pAPOPTIN + pIL-18 secreted high levels of the Th1 
      cytokine IL-2 and IFN-gamma, indicating that the regression of tumor cells is 
      related to a Th1-type dominant immune response. These results demonstrate that 
      vaccination with Apoptin together with IL-18 may be a novel and powerful strategy 
      for cancer immunotherapy.
FAU - Lian, Hai
AU  - Lian H
AD  - Genetic Engineering Laboratory, Academy of Military Medical Sciences, 1068 
      Qinglong Road, Changchun, Jilin 130062, People's Republic of China.
FAU - Jin, Ningyi
AU  - Jin N
FAU - Li, Xiao
AU  - Li X
FAU - Mi, Zhiqiang
AU  - Mi Z
FAU - Zhang, Jingmin
AU  - Zhang J
FAU - Sun, Lili
AU  - Sun L
FAU - Li, Xuemei
AU  - Li X
FAU - Zheng, Hongling
AU  - Zheng H
FAU - Li, Ping
AU  - Li P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060610
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Capsid Proteins)
RN  - 0 (Interleukin-18)
RN  - 0 (VP3 protein, Chicken anemia virus)
SB  - IM
MH  - Animals
MH  - Capsid Proteins/genetics/immunology/*pharmacology
MH  - Carcinoma, Lewis Lung/immunology/*therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Transfer Techniques
MH  - Genetic Therapy/*methods
MH  - Interleukin-18/genetics/immunology/*pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - T-Lymphocytes/immunology
MH  - Transfection
PMC - PMC11031098
EDAT- 2006/06/13 09:00
MHDA- 2007/02/14 09:00
PMCR- 2006/06/10
CRDT- 2006/06/13 09:00
PHST- 2006/02/07 00:00 [received]
PHST- 2006/03/28 00:00 [accepted]
PHST- 2006/06/13 09:00 [pubmed]
PHST- 2007/02/14 09:00 [medline]
PHST- 2006/06/13 09:00 [entrez]
PHST- 2006/06/10 00:00 [pmc-release]
AID - 178 [pii]
AID - 10.1007/s00262-006-0178-y [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2007 Feb;56(2):181-92. doi: 10.1007/s00262-006-0178-y. 
      Epub 2006 Jun 10.